GDF‐15 showed a significant correlation with all cardiac biomarkers [r = .46, P < .001 for NT‐proBNP; r = .46, P < .001 for hsTnT; r = .47, P < .001 for MR‐proANP; r = .59, P < .001 for MR‐proADM; r = .50, P < .001 for CT‐proET1 and r = .34, P < .001 for copeptin], the inflammatory markers [r = .31, P < .001 for CRP, r = .23, P < .001 for SAA and r = .14, P = .002 for IL‐6] and other routine laboratory parameters generally associated with outcome in cancer patients [r = −.42, P < .001 for albumin and r = −.28, P < .001 for haemoglobin]. This evidence concerns the gene IL6 and cancer.